Lessons from the AHRQ PSI Validation Pilot Project AHRQ QI Users Meeting September 10, 2008 Presenter: Patrick S. Romano, MD MPH; Professor, UC Davis Center.

Slides:



Advertisements
Similar presentations
Adverse Patient Safety Events: Costs of Readmissions and Patient Outcomes Following Discharge Didem M. Bernard, Ph.D. William E. Encinosa, Ph.D.
Advertisements

VALIDATING AHRQ PATIENT SAFETY INDICATORS with the VA NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM POSTOPERATIVE ADVERSE EVENTS Dennis Tsilimingras, M.D.,
Variations in Quality Outcomes Among Hospitals in Different Types of Health Systems, Askar Chukmaitov, M.D., M.P.A. Askar Chukmaitov, M.D.,
Differences in adverse events detected using different methods of identification? James M Naessens; Claudia R Campbell; Bjorn Berg; John J Lefante; Arthur.
Session 3C: Overview of the AHRQ Quality Indicators Thursday, September 27, :30 pm to 5:00 pm ET.
Leifur Bardarson MD Landspitali - University Hospital ICELAND A SSESSING P ATIENT S AFETY T HROUGH A DMINISTRATIVE D ATA A DAPTING AND I MPROVING E XISTING.
Changes to Performance-Based Payment Programs
CONTINUOUS QUALITY IMPROVEMENT Continuous Quality Stony Brook Medicine.
Current evidence and emerging methods regarding validation of the AHRQ QIs Patrick S. Romano, MD MPH UC Davis Center for Healthcare Policy and Research.
VTE Prophylaxis Alert to providers and nursing Go live June 24, 2014.
Collaborative to Reduce Healthcare Associated Infections
Overview of the AHRQ QI Toolkit for Hospitals Courtney Gidengil, MD MPH Peter Hussey, PhD RAND Corporation.
AHRQ Quality Indicators Toolkit Tool A.2 Instructions.
William B Munier, MD, MBA, Director Center for Quality Improvement and Patient Safety Agency for Healthcare Research and Quality AHRQ Annual Conference.
Day 1: Session III Implications of ICD-9-CM Coding Rules for Measuring QIs Presenters: Patrick Romano, UC Davis Rita Scichilone, American Health Information.
2012 Quality and Patient Safety Performance Results Annual Report The Quality Committee of the Board Confidential & Privileged Peer Review Materials; Pages.
Refinement and Validation of the AHRQ Patient Safety Indicators Developed by UC-Stanford Evidence Based Practice Center Funded by the Agency for Healthcare.
Agency For Healthcare Quality and Research Quality Indicators NH Health Care QA Commission AHRQ Subcommittee Report July 31, 2009.
IndicatorGoalHC?JulAugSepOctNovDecJanFebMarAprMayJunYTD Worksite Safety Indicators Total Recordable Injury Incident Rate Never Occurring 100%?
Assessing Patient Safety through Administrative Data: Adapting and Improving Existing Systems Patrick S. Romano, MD MPH Professor of Medicine and Pediatrics.
OECD Health Care Quality Indicator Project Prague March 5th 2009 Sandra Garcia Armesto on behalf of the HCQI team.
POSITIVE PREDICTIVE VALUE OF AHRQ PATIENT SAFETY INDICATORS IN A NATIONAL SAMPLE OF HOSPITALS AcademyHealth Annual Research Meeting June 9, 2008 Team presenter:
1 Northwestern Memorial HealthCare AHRQ Patient Safety Indicators: Constructive Use for Improvement Presented to AHRQ Annual Conference September 15, 2009.
Adapting AHRQ Patient Safety Indicators to QIO Data Jocelyn Andrel, MSPH Charles P. Schade, MD, MPH Patricia Ruddick, RN, MSN.
1 Terri Conner,PhD Nybeck Analytics Partnership for Patients 14 th May 2012 USE OF MEDICARE DIAGNOSIS AND PROCEDURE CODES TO IMPROVE DETECTION OF SURGICAL.
Quality Indicators™: Moving Ahead AHRQ Annual Conference 2012 Mamatha Pancholi, MS, Project Officer, Quality Indicators September 11, 2012.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care Improving Administrative Data for Public Reporting Anne Elixhauser.
Preventable Hospitalization Costs and Mapping Tool John Bott Center for Delivery, Organization, and Markets July 21, 2010.
Explaining the Volume-Cost Relationship for Cancer Surgery Vivian Ho PhD a Meei-Hsiang Ku-Goto MA a and Thomas Aloia MD b a Rice University and Baylor.
How Much Does Medicare Pay Hospitals for Adverse Events? Building the Business Case for Investing in Patient Safety Improvement Chunliu Zhan, MD, PhD,
Comparative Rankings of Hospital Quality – Does the Data Source Matter? Anne Elixhauser, Ph.D. Bernard Friedman, Ph.D. June 26, 2005 AcademyHealth Research.
ARE YOU READY? For HAC’s – October 1, 2008 Kathy Whitmire September 2008.
What do we know about overall trends in patient safety in the USA? Patrick S. Romano, MD MPH Professor of Medicine and Pediatrics University of California,
AHRQ Quality Validation Pilot Process and Tools Patricia Zrelak, RN, PhD UC Davis Center for Healthcare Policy and Research AHRQ QI Users Meeting Bethesda,
What is Clinical Documentation Integrity? A daily scavenger hunt.
1 1 Survey of Patient Safety Culture in U.S. Hospitals: External Validity Analyses Russ Mardon, Ph.D. Westat 2008 AHRQ Annual Conference Westat 1650 Research.
Using AHRQ Patient Safety Indicators to Improve Quality: The Stanford Hospital Experience John M. Morton, MD, MPH, FACS Associate Professor Director of.
AHRQ Quality Indicators 2005 AHRQ QI User Meeting September 26, 2005 Marybeth Farquhar, AHRQ.
Day 2: Session III Considerations in Comparative and Public Reporting Presenters: Patrick Romano, UC Davis Shoshanna Sofaer, Baruch College AHRQ QI User.
Development & Evaluation of the Forthcoming AHRQ Neonatal Quality Measures AHRQ 2007 Annual Conference, Session 3C Overview of the AHRQ Quality Indicators.
Use of Outcome Measures in Payment Reform: Rationale Patrick S. Romano, MD MPH UC Davis Center for Healthcare Policy and Research AHRQ Annual Conference.
Rates of Patient Safety Indicators (PSIs) Rates of Patient Safety Indicators (PSIs) among VA Patients in the First Two Years among VA Patients in the First.
Hospital-Acquired VTE: What We Have Learned Martha J. Radford, MD Chief Quality Officer NYU Langone Medical Center September 2009.
AHRQ QI User Meeting Validation Pilot Lessons Learned Laura Puzniak, PhD, MPH Friday, September 28, 2007.
Risk Management / CQI Nutr 564: Management Summer 2005.
Going Public Ben Yandell, PhD, CQE Clinical Information Analysis Norton Healthcare, Louisville, KY
AHRQ PSIs and IQIs in National Pay for Reporting September 14, 2009 AHRQ QI Conference Shaheen Halim, Ph.D. Centers for Medicare & Medicaid Services.
AHRQ Quality Indicators NQF Update Marybeth Farquhar, PhD, MSN, RN QI Users Meeting AHRQ 2 nd Annual Conference Rockville, MD September 10, 2008.
Panel Reviews of the AHRQ QIs: AHRQ and NQF panels Sheryl Davies, MA Stanford University.
Hospital Measures Reporting in Ohio Michele Shipp, MD, DrPH AHRQ QUALITY INDICATORS USERS MEETING Wednesday September 9, 2008 AHRQ ANNUAL CONFERENCE 2008.
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, Pharmacy, CCE Confidential:
BlueCross BlueShield of Illinois a Division of Health Care Service Corporation (HCSC), a Mutual Legal Reserve Company Blue Cross Blue Shield of Illinois.
Iowa Healthcare Collaborative - Past, Present, and Future Use of AHRQ Quality Indicators Lance Roberts 2009 AHRQ Annual Conference September 24,
Risk Management / CQI Nutr 564: Management Summer 2005.
1 Quality of Care and Patient Safety: Impact on Healthcare January 22, 2009 Presenter: F. Lisa Murtha, Practice Leader and Managing Director, Huron Consulting.
Development and Testing of the AHRQ QI Toolkit for Hospitals Donna O. Farley, PhD Peter Hussey, PhD RAND Corporation.
Future Validation and Improvement of the AHRQ QI AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Kathryn McDonald.
Performance Measures: CMS Hospital Inpatient Quality Reporting Program (IQR)Update As of November 2012.
Question Are Medical Emergency Team calls effective in reducing cardiopulmonary arrest rates in the general medical surgical setting? Problem The degree.
Dr. Rashida Abdelfattah FACULTY OF NURSING SCIENCES University of Khartoum.
MQMS: Patient Safety Among Medicare Beneficiaries Arnold Chen, M.D., M.Sc. (MPR) David Hunt, M.D. (CMS) Sheila Roman, M.D., M.P.H. (CMS) Lein Han, Ph.D.
Future Validation and Improvement of the AHRQ QI AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Kathryn McDonald.
AHRQ QI Guide to Comparative Reporting AHRQ Annual Conference September 10, 2008 Bethesda, MD Presented by Sheryl Davies.
The Department of Quality and Risk Management
Venous Thromboembolism Prophylaxis (VTE)
PATIENT SAFETY AND DOCUMENTATION: Connecting the Dots
Quality How is this LOM Metric measured in the LEM?
Inpatient Quality Coding It’s Not Just About What you Get Paid
Presentation transcript:

Lessons from the AHRQ PSI Validation Pilot Project AHRQ QI Users Meeting September 10, 2008 Presenter: Patrick S. Romano, MD MPH; Professor, UC Davis Center for Healthcare Policy and Research Team: Mamatha Pancholi and Marybeth Farquhar (AHRQ); Jeffrey Geppert and Teresa Schaaf (Battelle Memorial Institute); Sheryl Davies and Kathryn McDonald (Stanford); Garth Utter, Richard White, Daniel Tancredi, Patricia Zrelak, Ruth Baron, and Banafsheh Sadeghi (UC Davis)

Outline What do we mean by “validation”? What do we mean by “validation”? Goals Goals Methods Methods Results Results Future plans Future plans Implications Implications

Validation A valid measure accurately represents the true state of the phenomenon being measured (i.e., “free of systematic error”). Content (aka consensual) validity is the degree to which a measure “on its face” adequately samples all relevant domains of the concept of interest. Content (aka consensual) validity is the degree to which a measure “on its face” adequately samples all relevant domains of the concept of interest. Criterion (aka concurrent) validity is the degree to which a measure generates data that agree with data from a better (“gold standard”) approach to measuring the same characteristic. Criterion (aka concurrent) validity is the degree to which a measure generates data that agree with data from a better (“gold standard”) approach to measuring the same characteristic. Predictive validity is the degree to which a measure successfully predicts an outcome of interest. Predictive validity is the degree to which a measure successfully predicts an outcome of interest. Construct (aka convergent/discriminant) validity is the degree to which a measure correlates with other measures, based on a construct that is grounded in prior literature or a sound conceptual framework Construct (aka convergent/discriminant) validity is the degree to which a measure correlates with other measures, based on a construct that is grounded in prior literature or a sound conceptual framework

Content validity established Modified RAND/UCLA Appropriateness Method Physicians of various specialties/subspecialties, nurses, other professionals (e.g., midwife, pharmacist) were nominated Each potential indicator was assigned to one or two panels All panelists rated all assigned indicators (1-9) on overall usefulness and other dimensions Pre-conference ratings and comments were collected Individual ratings were returned to panelists with distribution of ratings and other panelists’ comments Telephone conference call(s) focused on high-variability items and panelists’ suggestions, which were adopted only by consensus Post-conference ratings and comments were collected Excluded indicators rated “Unclear,” “Unclear-,” or “Unacceptable”: – – Median score <7, OR – – At least 2 panelists rated the indicator in each of the extreme 3- point ranges

Content validity 48 indicators reviewed in total – – 37 reviewed by multispecialty panel – – 15 of those reviewed by surgical panel 20 “accepted” based on face validity – – 2 dropped due to operational concerns 17 “experimental” or promising indicators 11 rejected

OECD Expert panel review of PSI usefulness and “preventability” c a Panel ratings were based on definitions different than final definitions. For “Iatrogenic pneumothorax,” the rated denominator was restricted to patients receiving thoracentesis or central lines; the final definition expands the denominator to all patients (with same exclusions). For “In-hospital fracture” panelists rated the broader Experimental indicator, which was replaced in the Accepted set by “Postoperative hip fracture” due to operational concerns. b Vascular complications were rated as Unclear (-) by surgical panel; multispecialty panel rating is shown here. c “ Acceptable” and “acceptable-” both have median score 7-9; “acceptable” means no more than 1 or 2 panelists rated indicator below 7whereas “acceptable-” means no more than 1 or 2 panelists rated indicator in 1-3 range.

National Quality Forum evidence review National Voluntary Consensus Standards for Hospital Care: Additional Priorities, 2007 Purpose was to seek additional voluntary consensus standards for measuring the performance of the nation’s general acute care hospitals, including: 1) morbidity and mortality measures, 2) anesthesia and surgery measures, 3) measures for utilization rates for risky or often unnecessary procedures, 4) surgical volume and mortality measures, 5) readmission rates and length of stay (LOS) rates, 6) pain assessment, and 7) pediatric asthma. Convened Technical Assessment Panels for Patient Safety, Surgery and Anesthesia, Pediatric, Public Reporting, Length of Stay and Readmission

NQF review results QI Name Endorsed date Death in Low-Mortality DRGs (PSI 2)5/15/08 Death Among Surgical Patients w/ Treatable Complications (PSI 4)5/15/08 Foreign Body Left During Procedure-Provider level (PSI 5)5/15/08 Iatrogenic Pneumothorax-Provider level (PSI 6)5/15/08 Postoperative DVT or PE (PSI 12)7/31/08 Postoperative Wound Dehiscence-Provider level (PSI 14)5/15/08 Accidental Puncture or Laceration-Provider level (PSI 15)5/15/08 Transfusion Reaction-Provider level (PSI 16)5/15/08 Yellow = proposed HACs; Cyan = proposed RHQDAPU

Predictive validity established: Impact of preventing a PSI on mortality, LOS, charges NIS 2000 analysis by Zhan & Miller, JAMA 2003;290: Indicator Δ Mort (%)Δ LOS (d)Δ Charge ($) Postoperative septicemia $57,700 Selected infections due to medical care ,700 Postop abd/pelvic wound dehiscence ,300 Postoperative respiratory failure ,500 Postoperative physiologic or metabolic derangement ,800 Postoperative thromboembolism ,700 Postoperative hip fracture ,400 Iatrogenic pneumothorax ,300 Decubitus ulcer ,800 Postoperative hemorrhage/hematoma ,400 Accidental puncture or laceration ,300 Excess mortality, LOS, and charges computed from mean values for PSI cases and matched controls.

Predictive validity established: Impact of preventing a PSI on mortality, LOS, charges VA PTF 2001 analysis by Rivard et al., Med Care Res Rev ; 65(1):67-87 Indicator Δ Mort (%)Δ LOS (d)Δ Cost ($) Postoperative septicemia $31,264 Selected infections due to medical care ,816 Postop abd/pelvic wound dehiscence ,905 Postoperative respiratory failure ,745 Postoperative physiologic or metabolic derangement Postoperative thromboembolism ,205 Postoperative hip fracture Iatrogenic pneumothorax ,633 Decubitus ulcer ,713 Postoperative hemorrhage/hematoma ,863 Accidental puncture or laceration ,359 Excess mortality, LOS, and charges computed from mean values for PSI cases and matched controls.

AHRQ PSI Validation Pilot Goals Gather evidence on the criterion validity of the PSIs based on medical record review Gather evidence on the criterion validity of the PSIs based on medical record review Improve guidance about how to interpret & use the data Improve guidance about how to interpret & use the data Evaluate potential refinements to the specifications Evaluate potential refinements to the specifications Develop medical record abstraction tools Develop medical record abstraction tools Develop mechanisms for conducting validation studies on a routine basis Develop mechanisms for conducting validation studies on a routine basis

Positive Predictive Value The positive predictive value or post-test probability is the proportion of flagged cases who actually had the event. The positive predictive value or post-test probability is the proportion of flagged cases who actually had the event. The Positive Predictive Value (PPV) can be further defined as: The Positive Predictive Value (PPV) can be further defined as:

PSI Validation Pilot Methods Retrospective cross-sectional study design Retrospective cross-sectional study design Volunteer sample of collaborative partners Volunteer sample of collaborative partners – Facilitating organizations (e.g., Arizona) – Hospital systems – Individual hospitals Sampling based on administrative data Sampling based on administrative data Sampling probabilities assigned using AHRQ QI software to generate desired sample size locally (30) and nationally (240 per indicator) Sampling probabilities assigned using AHRQ QI software to generate desired sample size locally (30) and nationally (240 per indicator)

Data collection methods Each hospital identified chart abstractors Each hospital identified chart abstractors Training occurred via webinars Training occurred via webinars Medical record abstraction tools & guidelines Medical record abstraction tools & guidelines – Pretested in the Sacramento area – Targeted the ascertainment of the event, risk factors, evaluation & treatment, and related outcomes Coordinating center entered data from paper forms Coordinating center entered data from paper forms

PSI Validation Pilot Timeline ■ 10 indicators- divided into 2 phases of 5 each ■ Phase I review-  Training early 2007  Chart review 4 month process  2 nd Qtr 2006 through 1 st Qtr 2007 (but some hospitals had to reach back as far as 4 th Qtr 2005) ■ Phase II review –  Awaiting OMB approval  Pre-pilot (6 hospitals) now underway Phase III –sensitivity determination

PSI Validation Pilot Phases Phase IPhase II Accidental puncture and laceration Foreign body left in during procedure Selected infection due to medical care Postoperative hemorrhage or hematoma Postoperative pulmonary embolism or deep vein thrombosis Postoperative physiologic and metabolic derangement Postoperative sepsisPostoperative respiratory failure Iatrogenic pneumothoraxPostoperative wound dehiscence

PSI Validation Pilot Samples Phase IHospitalsSample Accidental puncture and laceration43249 Iatrogenic pneumothorax38205 Postoperative PE/DVT37155 Selected Infection due to Medical Care37189 Postoperative Sepsis33164 Overall47967

N=249 N=249 91% (95% CI = 86-94%) PPV or true events 91% (95% CI = 86-94%) PPV or true events 9% (n=23) were false positives 9% (n=23) were false positives – 7% (n=18) miscoded 4 had disease-related lesions (perforated appendix or ischemic colon, ruptured AA, rectovesical fistula) 4 had disease-related lesions (perforated appendix or ischemic colon, ruptured AA, rectovesical fistula) 7 had a different complication (4 bleeding due to operative conduct, 1 surgical site infection, 1 dislodged gastrostomy tube, 1 periprosthetic fracture) 7 had a different complication (4 bleeding due to operative conduct, 1 surgical site infection, 1 dislodged gastrostomy tube, 1 periprosthetic fracture) 7 cases had no apparent event other than normal operative/procedural conduct (intentional, rule-out) 7 cases had no apparent event other than normal operative/procedural conduct (intentional, rule-out) – 2% POA (related to an earlier episode of care) Accidental Puncture or Laceration

Characteristics of confirmed cases (N=226) – – 170 (75%) were potentially consequential – – Most were related to an abdominal or pelvic procedure 51 (30%) enterotomy or other perforation of the GI tract 42 (25%) bladder injury 33 (19%) dural tear 27 (16%) vascular injury – – 132 (78%) involved a reparative procedure at the time of occurrence – – 19 (11%) required a return to the OR (one death)

Iatrogenic pneumothorax N=205 N=205 78% (95% CI = 73-82%) PPV or true events that occurred during the hospitalization 78% (95% CI = 73-82%) PPV or true events that occurred during the hospitalization 11% were false positives 11% were false positives – 7% (n=14) present or suspected at admission, most (n=8) transferred in – 4% no documentation of event (miscoded), but some with suspicion (n=3) 11% had exclusionary diagnosis or procedure (e.g., trauma, metastatic cancer) 11% had exclusionary diagnosis or procedure (e.g., trauma, metastatic cancer)

Iatrogenic pneumothorax Characteristics of confirmed cases (N=156) – – 9 (6%) transthoracic needle aspiration or biopsy – – 66 (47%) central venous catheter placement Only 4 used sonographic and 7 fluoroscopic guidance – – 59 (40%) other invasive procedures on or near the neck or chest wall 37 catheterization, pacemaker insertion 3 laparoscopic procedures 8 nephrectomy/renal procedures 2 operations involving the spinal canal 9 Other procedures – – 5 (5%) mechanical ventilation – – 1 (1%) cardiopulmonary resuscitation

Postoperative DVT or PE N = 155 N = 155 Coding perspective: Coding perspective: – PPV = 83% (95% CI = 73-95%) – 17% were false positives 10% (n=12) POA 10% (n=12) POA 7% (n=8) no documentation of VTE (miscoded) 7% (n=8) no documentation of VTE (miscoded) Clinical perspective: Clinical perspective: – PPV = 48% (95% CI = 33-61%) – Additional false positives due to preoperative VTE (20%), upper extremity DVT (9%), superficial or unspecified vein (6%)

Comparing PPV estimates with UHC sample for postoperative DVT/PE UHC Cohort (n=450)CodingClinical Sensitivity80% (46- 00%)100% Specificity99.5% ( %)98.6% ( %) Positive Predictive Value72% (67-79%)44% (36-52%) Negative Predictive Value99.6% ( %)100% AHRQ Cohort (n=121) Positive Predictive Value83% (73-95%)48% (33-61%)

Selected Infection due to Medical Care N=191 N=191 61% (95% CI = 51-71%) were true events that occurred during the index hospitalization 61% (95% CI = 51-71%) were true events that occurred during the index hospitalization 39% were false positives 39% were false positives – 7% (n=14) had exclusionary diagnosis – 20% (n=39) were present on admission, with no new infection – 12% (n=23) had no documentation of infection

Selected Infection due to Medical Care N=115 with new infection – – 106 with new infection – – 9 with POA + new infection Majority related to central lines (n= 53) – – 35 ** cases due to non-tunneled central lines (SC, IJ, Fem) Mean 11 days (7 days SD), range 2-35 days (n=33) – – 17 cases associated with PICC lines Mean 13.4 days (7.7 days SD), range 2-35 days 26 cases related to other types of catheters (3 arterial lines, 4 long-term vascular access ports, 3 ET, 8 IV, 1 urinary, 2 other) * Difficult review- some earlier termination by abstractors ** 2 cases had extreme values of 101 and 374 days were excluded from calculation

Postoperative Sepsis N=164 N=164 41% (95% CI = 28-54%) were true events that occurred during the hospitalization 41% (95% CI = 28-54%) were true events that occurred during the hospitalization 59% were false positive 59% were false positive – 17% had no documentation of bacteremia, septicemia, sepsis or SIRS – 17% had infection (=14%) or sepsis (=3%) POA – 25% did not have elective surgery

Summary of PPVs Preliminary estimates PSIPPV% Accidental puncture or laceration 91% Iatrogenic pneumothorax 78% Postoperative DVT/PE 48-83% Selected infections due to medical care 61% Postoperative sepsis 41% PPVs high for NQF-endorsed indicators

Recognizing limitations Not all data elements of interest available via chart review Not all data elements of interest available via chart review Time constraints (minimize burden on collaborators) Time constraints (minimize burden on collaborators) Inter-hospital variation in documentation and abstraction Inter-hospital variation in documentation and abstraction Volunteer sample; time periods varied slightly across hospitals Volunteer sample; time periods varied slightly across hospitals

Further analysis of potential preventability Further analysis of potential preventability Evaluation of alternative ICD-9-CM specifications Evaluation of alternative ICD-9-CM specifications – Can we improve PPV? Establish ongoing infrastructure for validation Establish ongoing infrastructure for validation Estimate sensitivity of 10 indicators (including Foreign Body, Pneumothorax, Wound Dehiscence, and Accidental Puncture and Laceration) Estimate sensitivity of 10 indicators (including Foreign Body, Pneumothorax, Wound Dehiscence, and Accidental Puncture and Laceration) AHRQ QI Validation Pilot Future plans

Policy implications Coding changes needed to enhance specificity and PPV in some areas Coding changes needed to enhance specificity and PPV in some areas – AHRQ proposed new codes for DVT – CMS proposed new code for catheter- associated bloodstream infection With these changes, 3 of 5 PSIs tested in Phase 1 should have high PPV With these changes, 3 of 5 PSIs tested in Phase 1 should have high PPV These indicators have been endorsed by NQF These indicators have been endorsed by NQF More data on sensitivity (false negatives) are needed to avoid rewarding hospitals that underreport More data on sensitivity (false negatives) are needed to avoid rewarding hospitals that underreport

AHRQ project team AHRQ project team – Mamatha Pancholi &Marybeth Farquhar Battelle training and support team Battelle training and support team – Laura Puzniak & Lynne Jones All of the validation pilot partners! All of the validation pilot partners!Acknowledgments